Ignite Creation Date:
2025-12-24 @ 2:06 PM
Ignite Modification Date:
2025-12-27 @ 9:28 PM
Study NCT ID:
NCT00729495
Status:
COMPLETED
Last Update Posted:
2009-05-14
First Post:
2008-08-05
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib
Sponsor:
POZEN
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
D1120C00007
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Mark Sostek, MD, Medical Science Director, Development Project
Old Organization:
AstraZeneca Pharmaceuticals
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |